Abstract:Abstract Background. Immune checkpoint molecules are essential for modulating immune responses and maintaining self-tolerance. While immune checkpoint inhibitors have improved the treatment of a broad spectrum of cancers, many of them are also believed to play a critical role in the induction of immune related adverse events (irAEs) such as autoimmune and inflammatory diseases. For example, patients receiving anti-PD-1 based therapy frequently develop colitis. In addition, dysfunctional PD-1 signalling has also been linked to increasing susceptibility to autoimmune and inflammatory diseases. Therefore, immune checkpoint molecule agonist which could, like their natural ligands, confer a great potential in suppressing excessively activated immune response observed in autoimmune and inflammatory diseases. Methods. In the first part, the proinflammation effects of a Pembrolizumab analogue was evaluated in a MC38-OVA colorectal tumor bearing mice treated with or without DSS. In the second part, an anti-hPD-1 agonistic antibody at 10 mg/kg was evaluated in acute DSS IBD model. Results. In the MC38-OVA colorectal cancer model, mice treated with Pembrolizumab analogue only or Pembrolizumab analogue plus 1.5% DSS showed significant tumor growth inhibition (100% TGI and 92.01% TGI, respectively at Day 27) compared to their respective control group, which suggests this Pembrolizumab analogue induced robust anti-tumor immunity against MC38-OVA tumors. Notably, 8/8 mice treated with Pembrolizumab analogue only showed complete tumor regression, while only 5/8 mice treated with Pembrolizumab analogue plus DSS showed complete tumor regression. Taken together, these results suggest DSS treatment leading to a proinflammatory context could compromise anti-hPD-1 anti-tumor efficacy. Moreover, mice treated with Pembrolizumab analogue plus DSS also showed 3.59% more Body Weight Loss (BWL) in comparison to 1.5% DSS only group, suggesting that Pembrolizumab analogue could exacerbate DSS induced colitis. In the acute DSS IBD model, mice treated with an agonistic anti-hPD-1 antibody showed significantly lower disease score (DAI 5.3 vs DAI 2.4) and less BWL (BWL 13.44% vs BWL 3.31%) in comparison to isotype control group. In addition, pathology results showed that mice treated with agonistic anti-hPD-1 exhibits significantly less inflammatory cell infiltration and colonic lesions when compared to isotype control group. Conclusion. In summary, we reported in this study that blocking of PD-L1/PD-1 signalling axis by a PD-1 antagonist activated T cell function which at the same time aggravated DSS induced colitis in mouse. In contrast, activation of PD-L1/PD-1 signalling pathway by a PD-1 agonist alleviated DSS induced colitis. Citation Format: Tao Yang, Rongfei Lu, kaixia lian, Likun Zhang, Dawei Wang, Xinhe Feng, Xiaoyu An, Jessie (Jingjing) Wang, Carl K. Edwards. PD-1/PD-L1 signalling axis, “a double-edged sword” in DSS induced colitis mouse model. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5134.

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

Altered interactions between circulating and tissue-resident CD8 T cells with the colonic mucosa define colitis associated with immune checkpoint inhibitors

Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis

Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities

Cancer Immunotherapy: The Checkpoint between Chronic Colitis and Colorectal Cancer

Microbiota-dependent activation of CD4 + T cells induces CTLA-4 blockade–associated colitis via Fcγ receptors

Checkpoint Inhibitor-Induced Colitis: An Update

Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration.

Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

Immune checkpoint inhibitor induced colitis and arthritis: A case report

Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor-mediated Colitis

Abstract 5134: PD-1/PD-L1 Signalling Axis, “a Double-Edged Sword” in DSS Induced Colitis Mouse Model

Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers

Colitis due to cancer treatment with immune check-point inhibitors – review of literature and presentation of clinical cases

Inflammatory Conditions Promote Resistance to Immune Checkpoint Inhibitors in High Microsatellite Instability Colorectal Cancer

Immunotherapy efficacy in colorectal cancer is dependent on activation of a microbial-metabolite-immune circuit

Cytokine-Induced Modulation of Colorectal Cancer